From professional translators, enterprises, web pages and freely available translation repositories.
as with other dna-damaging antineoplastic agents, secondary acute myeloid leukemias and myelodysplasias have been reported in patients having received combined treatment with doxorubicin.
bħal ma jiġri b' sustanzi antinejoplastiċi oħra li jagħmlu ħsara fid- dna, ġew rappurtati lewċemiji sekondarji majelodiċi akuti u majelojdisplażji f' pazjenti li jkunu ħadu trattament ikkombinat ma’ doxorubicin.
Last Update: 2011-10-23
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
leukemia in the docetaxel, doxorubicin and cyclophosphamide (tac) treated patients, the risk of delayed myelodysplasia or myeloid leukemia requires haematological follow-up.
lewkimja fil- pazjenti ittrattati b ’ docetaxel, doxorubicin u cyclophosphamide (tac), ir- riskju li jiżviluppaw myelodysplasia jew lewkimija tat- tip myeloid, fit- tard, jirrikjedi l- immoniterjar ematoloġiku wara t - trattament.
Last Update: 2012-04-10
Usage Frequency: 6
Quality:
